Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD

NCT02038829

COPD

COMPLETED PHASE2

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02347761

COPD

COMPLETED PHASE3

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01706536

COPD

COMPLETED PHASE2

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02948582

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, open-label, single-dose per dosing period, five-way crossover study in subjects 40 to 70 years of age with a diagnosis of moderate to severe COPD per Global Initiative for Chronic Obstructive Lung Disease guidelines. After a subject provides consent for study participation, there will be a Screening Period lasting up to 3 weeks to determine study eligibility and to allow for appropriate washout of prohibited medications.

Eligible subjects will be randomized to one of 10 treatment Sequences. There will be a minimum of a 7-day washout period between each treatment visit. At each visit, subjects will receive one dose of study medication according to the sequence assigned.

Subjects with a ≥ 20% decrease in forced expiratory volume in one second (FEV1) based on review of the Visit predose value compared with the Screening value will be evaluated by the investigator for continuation in the study.

Subjects taking theophylline will not be able to participate in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SUN-101 via eFlow nebulizer

50 mcg glycopyrrolate via Electronic Nebulizer

Group Type EXPERIMENTAL

SUN-101 via eFlow nebulizer

Intervention Type DRUG

50 mcg glycopyrrolate via Electronic Nebulizer

SUN-101 via eFlow nebulizer with activated charcoal

50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal

Group Type EXPERIMENTAL

SUN-101 via eFlow nebulizer with activated charcoal

Intervention Type DRUG

50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal

Seebri® Breezhaler®

63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI

Group Type ACTIVE_COMPARATOR

Seebri® Breezhaler®

Intervention Type DRUG

63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI

Seebri® Breezhaler® with activated charcoal

: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal

Group Type ACTIVE_COMPARATOR

Seebri® Breezhaler® with activated charcoal

Intervention Type DRUG

63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal

: Glycopyrrolate Injection

50 mcg glycopyrrolate via IV infusion

Group Type ACTIVE_COMPARATOR

Glycopyrrolate Injection

Intervention Type DRUG

50 mcg glycopyrrolate via IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SUN-101 via eFlow nebulizer

50 mcg glycopyrrolate via Electronic Nebulizer

Intervention Type DRUG

SUN-101 via eFlow nebulizer with activated charcoal

50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal

Intervention Type DRUG

Seebri® Breezhaler®

63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI

Intervention Type DRUG

Seebri® Breezhaler® with activated charcoal

63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal

Intervention Type DRUG

Glycopyrrolate Injection

50 mcg glycopyrrolate via IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glycopyrrolate Glycopyrrolate glycopyrronium, glycopyrronium bromide glycopyrronium, glycopyrronium bromide Glycopyrrolate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients 40 to 70 years-old, inclusive.
2. A clinical diagnosis of moderate to severe COPD according to the GOLD 2014 guidelines.
3. Current smokers or ex-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, or equivalent).
4. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1 ≥ 30% and ≤ 80% of predicted normal during the Screening Period.
5. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio ≤ 0.70 during the Screening Period.
6. Ability to perform reproducible spirometry according to the American Thoracic Society (ATS) and/or European Respiratory Society (ERS) guidelines (2005).
7. Subject, if female ≤ 70 years of age and of child bearing potential, must have a negative urine pregnancy test at Visit 1. Females of childbearing potential must be instructed to and agree to avoid pregnancy during the study and must use an acceptable method of birth control: a) an oral contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or injectable contraceptive for at least 1 month prior to entering the study with continued use throughout the study and for thirty days following participation; b) barrier method of contraception, eg, condom and /or diaphragm with spermicide while participating in the study; and/or c) abstinence.
8. Willing and able to remain at the study site for at least 24 hours for each treatment day.
9. Willing and able to provide written informed consent.
10. Willing and able to attend all study visits and adhere to all study assessments and procedures.

Exclusion Criteria

1. Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions that would, in the opinion of the Investigator, preclude the subject from safely completing the required tests or the study, or is likely to result in disease progression that would require withdrawal of the subject, included but not limited to the following:

* Unstable ischemic heart disease (diagnosis of myocardial infarction or admission for acute coronary syndrome) within 6 months of screening.
* Unstable cardiac arrhythmia or heart failure (change in treatment plan) within 6 months.
* Treatment for diabetes mellitus within 6 months of screening.
2. Current evidence or history of a clinically significant abnormality of cardiac rhythm and/or conduction findings.
3. Concomitant clinically significant respiratory disease other than COPD (eg, asthma, tuberculosis, bronchiectasis, or other non-specific pulmonary disease).
4. History of malignancy of any organ system treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma of the skin.
5. Recent history of COPD exacerbation requiring hospitalization or need for increased treatments for COPD within 6 weeks prior to the Screening Period.
6. Use of daily oxygen therapy \> 10 hours per day.
7. Use of oral, intravenous, or intramuscular steroids within 3 months prior to the Screening Period.
8. Respiratory tract infection within 6 weeks prior to or during the Screening Period.
9. Significant blood loss (\> 500 mL) or donated blood within 60 days preceding screening or plans to donate blood within 60 days after completing the study.
10. History of or clinically significant ongoing bladder outflow obstruction or history of catheterization for relief of bladder outflow obstruction within the previous 6 months.
11. History of narrow-angle glaucoma.
12. Prolonged QTc interval (\> 450 msec for males and \> 470 msec for females) during the Screening Period, or history of long QT syndrome.
13. Recent documented history (previous 12 months) of substance abuse.
14. .Positive urine drug screen at Visit 1 provided the subject is unable to produce a valid medical rationale for the test result (eg, prescription medication).
15. Positive HbsAg, Hepatitis C antibody, or HIV 1/2 antibody test at Screening.
16. History of hypersensitivity or intolerance to aerosol medications, β2-agonists, anticholinergics, or sympathomimetic amines.
17. Significant psychiatric disease that would likely result in the subject not being able to complete the study, in the opinion of the Investigator.
18. Participation in another investigational drug study where drug was received within 30 days prior to the Screening Period, or current participation in another investigational drug trial in which study treatment is being administered, including a SUN-101 study
19. Previously received SUN-101 (active treatment; formerly known as EP-101).
20. Previously received any glycopyrrolate product within 28 days of Screening.
21. Subject is taking theophylline.

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No